Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Yasuyoshi Morita, Takayuki Ikezoe, MD PhD, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, MD PhD, Naoko Hosono, MD PhD, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, MD PhD, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, MD PhD, Masahiro Kizaki, MD, Koichi Akashi, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134078

Published: 2020

Journal Articles

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

Takahiro Shima, MD PhD, Teppei Sakoda, MD, Tomoko Henzan, MD, Yuya Kunisaki, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD, Toshihiro Miyamoto, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142316

Published: 2020

Journal Articles

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Hitoshi Hanamoto, Yasuyoshi Morita, Motoshi Ichikawa, Yasuhito Nannya, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD, Tomoko Hata, Toshihiro Miyamoto, MD PhD, Hiroshi Kawabata, MD PhD, Kazuto Takeuchi, Hiroko Tanaka, Junji Kishimoto, Satoru Miyano, PhD, Itaru Matsumura, MDPhD, Seishi Ogawa, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD, Kinuko Mitani

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134483

Published: 2020

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 912.

https://doi.org/10.1182/blood-2019-129237

Published: 2019

Journal Articles

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2516.

https://doi.org/10.1182/blood-2019-129372

Published: 2019

Journal Articles

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Kiwamu Hatakeyama, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 631.

https://doi.org/10.1182/blood-2019-125670

Published: 2019

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

Kohta Miyawaki, MD PhD, Takuji Yamauchi, MD PhD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Hiroaki Miyoshi, MD PhD, Simon Osborne, PhD, Deborah Taylor, PhD, Koichi Ohshima, MD PhD, Koji Kato, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 396.

https://doi.org/10.1182/blood-2019-129613

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 3784.

https://doi.org/10.1182/blood-2019-129623

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses

Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Hidetoshi Irifune, MD, Masayasu Hayashi, MD PhD, Goichi Yoshimoto, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2702.

https://doi.org/10.1182/blood-2019-127779

Published: 2019

Journal Articles

Identification of GPAT1 As a Novel Therapeutic Target for Acute Leukemia By Inhibiting Leukemia Specific Metabolism

Hidetoshi Irifune, MD, Yu Kochi, MD, Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 1384.

https://doi.org/10.1182/blood-2019-125661

Published: 2019

Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 1390.

https://doi.org/10.1182/blood-2019-127047

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Koji Nagafuji, MD PhD, Toshihiro Miyamoto, MD PhD, Tetsuya Eto, MD PhD, Ryosuke Ogawa, MD PhD, Naoyuki Uchida, MD PhD, Ken Takase, MD, Noriaki Kawano, MD PhD, Tomoaki Fujisaki, MD PhD, Tomohiko Kamimura, MD PhD, Atsushi Wake, MD PhD, Hirokazu Okumura, MD PhD, Yasuhiko Miyazaki, MD PhD, Yasushi Takamatsu, MD PhD, Toshiro Kurokawa, MD PhD, Yuju Ohno, MD PhD, Shouhei Yokota, MP.Path, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2018-99-112848

Published: 2018

Journal Articles

Escape Hematopoiesis By HLA-B5401-Lacking Hematopoietic Stem Progenitor Cells in Male Patients with Acquired Aplastic Anemia

Kohei Hosokawa, MD PhD, Mahmoud Ibrahim Elbadry, MD, Hiroki Mizumaki, MD, Luis Espinoza, MD PhD, Noriharu Nakagawa, MD, Kazuhisa Chonabayashi, MD PhD, Yoshinori Yoshida, MD PhD, Takamasa Katagiri, PhD, Yoshitaka Zaimoku, MD PhD, Tatsuya Imi, MD, Nguyen Thi Mai Anh, MD, Yoichi Fujii, MD, Seishi Ogawa, MD PhD, Katsuto Takenaka, MD PhD, Koichi Akashi, MD PhD, Shinji Nakao, MD PhD

Blood (2018) 132 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2018-99-113756

Published: 2018

Journal Articles

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Takahiro Shima, MD PhD, Amanda G Davis, Daniel T Johnson, Yu Kochi, MD, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Junichiro Yuda, MD, Toshihiro Miyamoto, MD PhD, Jie-Hua Zhou, MD, Edward D. Ball, MD, Koichi Akashi, MD PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 885.

https://doi.org/10.1182/blood-2018-99-119199

Published: 2018

Journal Articles

Evaluation of TIM-3+ LSCs Is a Highly Sensitive MRD Monitoring Strategy to Predict AML Relapse after Allogenic Stem Cell Transplantation

Masayasu Hayashi, MD PhD, Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Hidetoshi Irifune, MD, Goichi Yoshimoto, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 1390.

https://doi.org/10.1182/blood-2018-99-116640

Published: 2018

Journal Articles

Identification of TIM-3/Gal-9 Autocrine Loop As a Novel Wnt-Ligands Independent Machinery for the Constitutive Activation of Canonical Wnt Pathway in AML-LSCs

Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2018-99-116897

Published: 2018

Journal Articles

Tax-Targeting Dendritic Cell Therapy for ATL: A Phase Ia/Ib Clinical Study

Motoaki Shiratsuchi, MDPhD, Tetsuya Fukuda, MD PhD, Tadafumi Iino, MD PhD, Atsuhiko Hasegawa, PhD, Jun-ichirou Yasunaga, MD PhD, Ken Watanabe, MD PhD, Akie Hirata, MD PhD, Hayato Utsunomiya, MD, Hirofumi Ohno, MD, Takashi Ishida, MD PhD, Koichi Akashi, MD PhD, Masao Matsuoka, MDPhD, Mari Kannagi, MD PhD, Youko Suehiro, MDPhD

Blood (2018) 132 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2018-99-113315

Published: 2018

NARROW

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses

Identification of GPAT1 As a Novel Therapeutic Target for Acute Leukemia By Inhibiting Leukemia Specific Metabolism

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Escape Hematopoiesis By HLA-B5401-Lacking Hematopoietic Stem Progenitor Cells in Male Patients with Acquired Aplastic Anemia

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Evaluation of TIM-3+ LSCs Is a Highly Sensitive MRD Monitoring Strategy to Predict AML Relapse after Allogenic Stem Cell Transplantation

Identification of TIM-3/Gal-9 Autocrine Loop As a Novel Wnt-Ligands Independent Machinery for the Constitutive Activation of Canonical Wnt Pathway in AML-LSCs

Tax-Targeting Dendritic Cell Therapy for ATL: A Phase Ia/Ib Clinical Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only